Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Develops oncology drugs for cancer patients, focused on immuno-oncology and precision medicines. Has 9 NDA approvals.
CStone Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted immuno-oncology therapies and precision medicines, headquartered in Suzhou, China. The publicly traded enterprise has built an extensive clinical pipeline consisting of 15 oncology drug candidates, successfully securing nine new drug application approvals across four distinct therapeutic products. Operating with a current workforce of 93 employees, the firm initially scaled its research and development operations following a $150 million Series A funding round before listing on the Hong Kong Stock Exchange. To advance its clinical trials and regional distribution throughout Greater China, the organization maintains strategic partnerships with Agios Pharmaceuticals and Hengrui. Furthermore, the company has received significant financial backing from prominent institutional investors, including Boyu Capital, Oriza Seed Venture Capital, and WuXi Healthcare Ventures. CStone Pharmaceuticals was founded in 2016.
CStone Pharmaceuticals has raised $405.7M across 2 funding rounds.
CStone Pharmaceuticals has raised $405.7M in total across 2 funding rounds.
CStone Pharmaceuticals has raised $405.7M across 2 funding rounds. Most recently, it raised $259.2M Series B in May 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 9, 2018 | $259.2M Series B | GIC | 3W Partners, 6 Dimensions Capital, ARCH Venture Partners, AVICT Global, Boyu Capital, CPE, Hillhouse Capital, Hongshan Capital Group (Sequoia Capital China), King Star Capital, Taikang, Terra Magnum Capital Partners, WuXi Healthcare Ventures, Yunfeng Capital | Announced |
| Jul 4, 2016 | $146.5M Series A | — | Boyu Capital, WuXi Healthcare Ventures | Announced |
CStone Pharmaceuticals has raised $405.7M in total across 2 funding rounds.
CStone Pharmaceuticals's investors include GIC, 3W Partners, 6 Dimensions Capital, ARCH Venture Partners, AVICT Global, Boyu Capital, CPE, Hillhouse Capital, Hongshan Capital Group (Sequoia Capital China), King Star Capital, Taikang, Terra Magnum Capital Partners.